# Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia

> **NCT03846414** · — · UNKNOWN · sponsor: **CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.** · enrollment: 1500 (estimated)

## Conditions studied

- Chemotherapy-induced Neutropenia
- Myelosuppression

## Interventions

- **DRUG:** PEG-rhG-CSF

## Key facts

- **NCT ID:** NCT03846414
- **Lead sponsor:** CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-02-13
- **Primary completion:** 2020-04-01
- **Final completion:** 2020-10-01
- **Target enrollment:** 1500 (ESTIMATED)
- **Last updated:** 2019-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03846414

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03846414, "Real World Study of PEG-rhG-CSF in Prevention of Chemotherapy-induced Neutropenia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03846414. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*